Related Experiment Video
Updated: Apr 29, 2026
10:53
Anionic Polymerization of an Amphiphilic Copolymer for Preparation of Block Copolymer Micelles Stabilized by π-π Stacking Interactions
Published on: October 10, 2016
12.8K
Pairwise polymer blends for oral drug delivery
Joyann A Marks1, Lindsay A Wegiel2, Lynne S Taylor2
1Macromolecules and Interfaces Institute, Department of Sustainable Biomaterials, College of Natural Resources and Environment, Virginia Tech, Blacksburg, Virginia 24061.
Journal of Pharmaceutical Sciences
|May 15, 2014
Summary
This study explored polymer blends for amorphous solid dispersions (ASDs). Several combinations, like HPMCAS/PVP, were found to be miscible, offering potential for drug solubility and bioavailability enhancement.
Area of Science:
- Polymer Science
- Materials Science
- Pharmaceutical Sciences
Background:
- Amorphous solid dispersions (ASDs) require polymers with specific properties to enhance drug solubility and bioavailability.
- A comprehensive understanding of polymer blend properties is crucial for optimizing ASD formulations.
- Commercially available polymers are essential components in developing effective ASDs.
Purpose of the Study:
- To identify miscible binary polymer blends for potential use in amorphous solid dispersions (ASDs).
- To evaluate the miscibility of various polymer pairs, including polyvinylpyrrolidone (PVP), Eudragit 100 (E100), hydroxypropyl methylcellulose acetate succinate (HPMCAS), carboxymethyl cellulose acetate butyrate (CMCAB), hydroxypropyl methylcellulose (HPMC), and cellulose acetate adipate propionate (CAAdP).
- To provide a foundation for further research into drug delivery applications of these polymer blends.
Main Methods:
- Preparation of pairwise blends of selected commercially available polymers.
- Assessment of blend miscibility using differential scanning calorimetry (DSC).
- Characterization of blend miscibility through FTIR spectroscopy and evaluation of film clarity.
Main Results:
- Several polymer combinations, including HPMCAS/PVP, HPMC/CMCAB, and PVP/HPMC, demonstrated miscibility across all proportions.
- Blends of Eudragit 100 (E100) with PVP and HPMC exhibited a miscibility gap.
- Identified miscible blends offer potential for balancing critical ASD performance criteria.
Conclusions:
- Miscible polymer blends, such as HPMCAS/PVP, HPMC/CMCAB, and PVP/HPMC, are identified as promising candidates for ASD formulations.
- The ability to balance properties through polymer blending is key for enhancing the solubility and bioavailability of poorly water-soluble drugs.
- These findings provide valuable tools for the development of advanced ASD formulations and drug delivery systems.
Related Concept Videos
01:11Oral Drug Delivery Systems: Delayed-Release Systems
218
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
218
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
159
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
159
01:23Oral Drug Delivery Systems: Introduction
275
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
275
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332